新型ACTIVE CONTROL释放系统下GORE TAG可顺应性胸主动脉支架的早期结果
该单中心回顾性研究纳入2017年9月至2018年6月连续30例接受C-TAG ACTIVE CONTROL胸主动脉腔内修复术的患者,评估术中细节与早期结局。技术成功率100%,30天临床成功率96.6%,早期随访无I型或III型内漏。分阶段释放与角度控制可能有助于挑战性主动脉弓病变的精准定位并预防鸟嘴效应。
要点
- C-TAG ACTIVE CONTROL在30例胸主动脉腔内修复中技术成功率达100%。
- 30天临床成功率为96.6%,早期随访无I型或III型内漏。
- 分阶段释放与角度控制可能有助于挑战性主动脉弓病变的精准定位。
核心结论
- C-TAG ACTIVE CONTROL在30例患者中显示出优异的早期结果,具有高释放精度和顺应性。
- 分阶段释放和角度控制附加功能可能对挑战性主动脉弓疾病大有帮助,允许精准定位并预防鸟嘴效应。
研究设计与样本
- 单中心回顾性研究,2017年9月至2018年6月连续纳入30例接受胸主动脉腔内修复术的患者。
- 使用新型GORE TAG可顺应性胸主动脉支架(C-TAG ACTIVE CONTROL;W. L. Gore & Associates)。
- 新系统提供50%中间释放步骤和近端支架移植物可选角度控制。
主要发现
- 所有患者支架移植物成功导入并释放至预期位置,完全隔绝主动脉疾病,无术中死亡,原发技术成功率100%。
- 1例急诊患者因持续性感染性休克于2天死亡,30天临床成功率96.6%。
- 中位随访107天(范围33-271天),晚期死亡率3.4%(1例患者于40天死于支架移植物感染)。
- 早期随访无I型和III型内漏,无患者需针对原治疗主动脉疾病行其他手术或腔内干预。
关键数值与推荐
- 适应证包括慢性夹层后和退行性动脉瘤、复杂性急性夹层、壁内血肿等,择期63.3%、紧急13.3%、急诊23.3%。
- 近端锚定区:LZ 2占23.3%,LZ 3占43.3%,LZ 4占33.3%。
临床怎么用
- 对于挑战性主动脉弓病变,可考虑使用C-TAG ACTIVE CONTROL的分阶段释放和角度控制功能以实现精准定位并预防鸟嘴效应。
- 需注意支架移植物感染风险,本研究中1例患者因此死亡。
局限性
- 单中心回顾性研究,样本量30例,随访时间较短(中位107天)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to describe single-center intraoperative details and early outcome of the new GORE TAG conformable stent graft with ACTIVE CONTROL (C-TAG ACTIVE CONTROL; W. L. Gore & Associates, Flagstaff, Ariz). METHODS: Between September 2017 and June 2018, a consecutive 30 patients underwent thoracic endovascular aortic repair with C-TAG ACTIVE CONTROL. This new system provides an intermediate deployment step at 50% and optional angulation control of the proximal part of the stent graft. Indications for thoracic endovascular aortic repair varied widely, including chronic postdissection and degenerative aneurysms, complicated acute dissections, and intramural hematomas, among others, in an elective (63.3%), urgent (13.3%), or emergent (23.3%) setting. The proximal landing zone (LZ) was LZ 2 in 23.3%, LZ 3 in 43.3%, and LZ 4 in 33.3%. Data were collected retrospectively and analyzed for technical and clinical success. RESULTS: In all patients, the stent graft was successfully introduced and deployed at the intended position, with complete exclusion of aortic disease and without intraoperative mortality (primary technical success, 100%). One emergent patient died at 2 days of ongoing septic shock (clinical success at 30 days, 96.6%). Median follow-up was 107 days (range, 33-271 days); late mortality was 3.4% (one patient died of stent graft infection at 40 days). Freedom from type I and type III endoleak at the early follow-up was 100%. No patients required other surgical or endovascular procedures for the primary treated aortic disease. CONCLUSIONS: Our reported initial experience in 30 patients with the C-TAG ACTIVE CONTROL showed excellent early results, with high deployment accuracy and conformability. The additional features of staged deployment and angulation control may be of great help in challenging aortic arch diseases, allowing precise positioning and preventing bird-beak effect.
引用
- Mariani C, van der Weijde E, Smith T, et al. The GORE TAG conformable thoracic stent graft with the new ACTIVE CONTROL deployment system. J Vasc Surg. 2019. PMID: 30922741. doi:10.1016/j.jvs.2018.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。